Do analysts prefer GLMD or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PHIO or GLMD?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$0.91 N/A

Is PHIO or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Galmed Pharmaceuticals N/A -35.32% -30.94%

Do analysts prefer GLMD or CMMB?

Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,328.57%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, GLMD or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$0.91 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is GLMD or CMMB more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -35.32% -30.94% Chemomab Therapeutics N/A -89.03% -79.68%

Do analysts rate XCUR or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XCUR or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Galmed Pharmaceuticals N/A -35.32% -30.94%

Does the media refer more to XCUR or GLMD?

In the previous week, Exicure and Exicure both had 3 articles in the media. Exicure's average media sentiment score of 0.67 beat Galmed Pharmaceuticals' score of 0.14 indicating that Exicure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate QCLS or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, QCLS or GLMD?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mymd Pharmaceuticals N/A N/A -$11.63M -$20.69 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$0.91 N/A

Is QCLS or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -35.32% beat Mymd Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mymd Pharmaceuticals N/A -76.40% -35.10% Galmed Pharmaceuticals N/A -35.32% -30.94%

Does the media refer more to QCLS or GLMD?

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Mymd Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.14 beat Mymd Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mymd Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galmed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Galmed Pharmaceuticals (GLMD) Competitors

$0.58 0.00 (-0.03%)

As of 11:33 AM Eastern

Compare

GLMD vs. AIMD, PHIO, CMMB, XCUR, and QCLS

Should you buy Galmed Pharmaceuticals stock or one of its competitors? MarketBeat compares Galmed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galmed Pharmaceuticals include Ainos (AIMD), Phio Pharmaceuticals (PHIO), Chemomab Therapeutics (CMMB), Exicure (XCUR), and Mymd Pharmaceuticals (QCLS).

How does Galmed Pharmaceuticals compare to Ainos?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Ainos (NASDAQ:AIMD) are related small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Ainos. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A
Ainos	$120K	98.69	-$14.77M	-$2.89	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Ainos. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Ainos. Galmed Pharmaceuticals' average media sentiment score of 0.14 beat Ainos' score of -0.47 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
Ainos	Neutral

Galmed Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Ainos has a beta of 2.46, meaning that its stock price is 146% more volatile than the broader market.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Galmed Pharmaceuticals' return on equity of -35.32% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Ainos	-11,912.10%	-186.12%	-66.07%

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Ainos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Ainos on 9 of the 12 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,233.33%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Phio Pharmaceuticals is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -35.32% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A

Phio Pharmaceuticals has a beta of 0.82, suggesting that its stock price is 18% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Phio Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.14 beat Phio Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Neutral
Galmed Pharmaceuticals	Neutral

Summary

Galmed Pharmaceuticals beats Phio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,328.57%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galmed Pharmaceuticals' return on equity of -35.32% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 19.8% of Galmed Pharmaceuticals shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Chemomab Therapeutics. Galmed Pharmaceuticals' average media sentiment score of 0.14 beat Chemomab Therapeutics' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
Chemomab Therapeutics	Neutral

Galmed Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

Summary

Galmed Pharmaceuticals beats Chemomab Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Exicure?

Exicure (NASDAQ:XCUR) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -35.32% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure and Exicure both had 3 articles in the media. Exicure's average media sentiment score of 0.67 beat Galmed Pharmaceuticals' score of 0.14 indicating that Exicure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exicure has a beta of 3.65, suggesting that its share price is 265% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Exicure has higher revenue and earnings than Galmed Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	18.86	-$4.95M	-$1.55	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A

Summary

Exicure and Galmed Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Mymd Pharmaceuticals?

Mymd Pharmaceuticals (NASDAQ:QCLS) and Galmed Pharmaceuticals (NASDAQ:GLMD) are related small-cap companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Galmed Pharmaceuticals' return on equity of -35.32% beat Mymd Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
Galmed Pharmaceuticals	N/A	-35.32%	-30.94%

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Mymd Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$0.91	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Mymd Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.14 beat Mymd Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mymd Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galmed Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mymd Pharmaceuticals has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Galmed Pharmaceuticals beats Mymd Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.80M	$11.66B	$6.87B	$13.01B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-0.63	791.59	280.56	25.50
Price / Sales	N/A	738.31	589.89	91.84
Price / Cash	N/A	71.54	72.11	49.40
Price / Book	0.20	10.90	13.11	6.11
Net Income	-$10.31M	$2.82B	$3.49B	$348.02M
7 Day Performance	2.77%	3.27%	3.55%	4.86%
1 Month Performance	0.84%	-1.90%	-2.46%	-2.02%
1 Year Performance	-64.05%	192.90%	73.70%	21.03%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.2514 of 5 stars	$0.58 0.0%	N/A	-64.8%	$3.80M	N/A	N/A	20	News Coverage
AIMD Ainos	0.4238 of 5 stars	$1.35 +3.0%	N/A	-42.9%	$11.49M	$120K	N/A	40	Earnings Report Gap Down
PHIO Phio Pharmaceuticals	3.6254 of 5 stars	$0.98 -2.9%	$14.00 +1,327.1%	-55.3%	$11.49M	N/A	N/A	10
CMMB Chemomab Therapeutics	2.4214 of 5 stars	$1.56 +8.7%	$25.00 +1,507.7%	-58.0%	$11.45M	N/A	N/A	20
XCUR Exicure	0.4898 of 5 stars	$1.79 +2.9%	N/A	-79.7%	$11.40M	$500K	N/A	50	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. AIMD, PHIO, CMMB, XCUR, and QCLS

How does Galmed Pharmaceuticals compare to Ainos?

Summary

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Summary

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Summary

How does Galmed Pharmaceuticals compare to Exicure?

Summary

How does Galmed Pharmaceuticals compare to Mymd Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. AIMD, PHIO, CMMB, XCUR, and QCLS

How does Galmed Pharmaceuticals compare to Ainos?

Which has higher valuation & earnings, GLMD or AIMD?

Do analysts prefer GLMD or AIMD?

Does the media refer more to GLMD or AIMD?

Which has more risk and volatility, GLMD or AIMD?

Is GLMD or AIMD more profitable?

Do institutionals & insiders hold more shares of GLMD or AIMD?

Summary

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Do analysts prefer PHIO or GLMD?

Is PHIO or GLMD more profitable?

Do institutionals & insiders have more ownership in PHIO or GLMD?

Which has stronger earnings & valuation, PHIO or GLMD?

Which has more volatility and risk, PHIO or GLMD?

Does the media favor PHIO or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Chemomab Therapeutics?

Do analysts prefer GLMD or CMMB?

Is GLMD or CMMB more profitable?

Do institutionals and insiders believe in GLMD or CMMB?

Which has preferable valuation & earnings, GLMD or CMMB?

Does the media prefer GLMD or CMMB?

Which has more risk & volatility, GLMD or CMMB?

Summary

How does Galmed Pharmaceuticals compare to Exicure?

Do insiders & institutionals have more ownership in XCUR or GLMD?

Is XCUR or GLMD more profitable?

Do analysts rate XCUR or GLMD?

Does the media refer more to XCUR or GLMD?

Which has more volatility and risk, XCUR or GLMD?

Which has preferable earnings & valuation, XCUR or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Mymd Pharmaceuticals?

Is QCLS or GLMD more profitable?

Which has better valuation and earnings, QCLS or GLMD?

Do analysts rate QCLS or GLMD?

Does the media refer more to QCLS or GLMD?

Which has more volatility & risk, QCLS or GLMD?

Do insiders and institutionals believe in QCLS or GLMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools